What Clinicians Need to Know About Available Therapeutic Options for COVID-19
Click here to view the recording with the integrated audio transcript using the password below.
“This content and conclusions are those of the author and presenter and do not necessarily represent the views of, nor should any endorsements be inferred by, the Centers for Disease Control and Prevention.”
The fully captioned video and edited transcript will be posted within the next few days.
This COCA Call will be held on Friday, March 27, 2020
Medications are available that can reduce chances of severe illness and death from COVID-19 infection. Oral antivirals are available that can reduce chances of severe illness and death from COVID-19 infection. The Food & Drug Administration issued emergency use authorizations for certain antiviral medications and monoclonal antibodies to treat mild to moderate COVID-19 in people who are more likely to get sick. The National Institutes of Health also provides COVID-19 treatment guidelines for healthcare providers for treating COVID-19 at home or in an outpatient setting. During this COCA Call, subject matter experts will present an overview of COVID-19 therapeutic options, including indications, efficacy, and distribution.
Pragna Patel, MD, MPH
Chief Medical Officer, COVID-19 Response
Centers for Disease Control and Prevention
Eric Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Clinical Guidelines Team
National Institutes of Health
John Farley, MD, MPH
Director, Office of Infectious Diseases
Office of New Drugs, Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Meg Sullivan, MD, MPH, FAAP
Chief Medical Officer
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services
Due to the high demand we anticipate for this COCA Call, we encourage participants to consider viewing on Facebook. To see the call live, please click on COCA’s Facebook Page.
Thursday, June 16, 2022,
2:00 PM – 3:00 PM ET
US: +1 669 254 5252
or +1 646 828 7666
or +1 551 285 1373
or +1 669 216 1590
US: +16692545252,,1603960029#,,,,*308026# or +16468287666,,1603960029#,,,,*308026#
Webinar ID: 160 396 0029Add to Calendar
Registration is not required.
Date: Thursday, June 16, 2022
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar begins, please click the link below to join:
Webinar ID: 160 396 0029
Dial-in US: +1 669 254 5252 or +1 646 828 7666 or +1 551 285 1373 or +1 669 216 1590
One-tap mobile: US: +16692545252,,1603960029#,,,,*308026# or +16468287666,,1603960029#,,,,*308026#
International numbers available: https://www.zoomgov.com/u/ab2qcyEiu7
At the conclusion of the session, the participant will be able to accomplish the following:
- Describe key points about COVID-19 rebound after use of Paxlovid.
- Describe Paxlovid use, prescribing, and availability.
- Discuss where to find more information about COVID-19 therapeutics and availability.
COCA Call Objectives
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
To receive continuing education (CE) for WC4520-061622 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – What Clinicians Need to Know About Available Therapeutic Options for COVID-19, Thursday, June 16, 2022, please visit TCEO and follow these 9 Simple Steps by Monday, July 18, 2022.
To receive continuing education (CE) for WD4520-061622 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – What Clinicians Need to Know About Available Therapeutic Options for COVID-19, Thursday, June 16, 2022, (Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, July 19, 2022, and Friday, July 19, 2024.
In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation
CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.
CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-22-057-L04-P and enduring JA4008229-0000-22-058-H04-P.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at firstname.lastname@example.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients, with the exception of Dr. Eric Daar who would like to disclose that he provides research support and is a consultant related to HIV for Gilead, Merck, and GSK/ViiV.
All of the relevant financial relationships listed for these individuals has been mitigated.
Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Farley’s discussion of unapproved drug products currently authorized under EUA for treatment of COVID-19.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.
- Physician Assistants
- Health Educators
- Other Clinicians
- Contact Information:email@example.com
- Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation:You may participate in the educational activity by viewing the program information above.